ArticleQuantitative imaging in medicine and surgery2025
Differentiation of breast cancer subtypes and correlation with biological status using functional magnetic resonance imaging: comparison with amide proton transfer-weighted imaging and diffusion-weighted imaging.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Amide proton transfer-weighted magnetic resonance imaging for the diagnosis of triple-negative breast cancer: a comparative study with diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2026Article
- Development and validation of a logistic regression model based on multiparametric MRI for differentiating triple-negative from non-triple-negative breast cancer.Quantitative imaging in medicine and surgery · 2026Article
- Multiparametric MRI and artificial intelligence for non-invasive HER2 assessment in breast cancer: a comprehensive review.Frontiers in medicine · 2026Review
- The Role of Tumor pH in Breast Cancer Imaging: Biology, Diagnostic Applications, and Emerging Techniques.Diagnostics (Basel, Switzerland) · 2025Review
- Time-dependent diffusion MRI for noninvasive molecular subtype differentiation and biological correlation in breast cancer: emphasizing the emerging three-tier HER2 classification.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiating molecular subtypes and identifying biological markers in breast cancer (BC) are essential for prognostic stratification and treatment selection. This study aimed to compare the effectiveness of amide proton transfer-weighted imaging (APTWI) and diffusion-weighted imaging (DWI) in differentiating molecular subtypes and predicting the biological status of BC. Methods: This retrospective study included 109 women (aged 50.8±10.8 years) with BC who underwent 3T APTWI and DWI between May 2023 and January 2024. Patients were categorized by molecular subtypes and expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67. Magnetization transfer ratio asymmetry (MTRasym) and apparent diffusion coefficient (ADC) values were measured. The area under the receiver operating characteristic (ROC) curve (AUC) was used to assess the performance of MTRasym and ADC values in distinguishing subtypes. Pearson's correlation analysis was used to examine the relationship between MTRasym, ADC values, and the Ki-67 proliferation index. Results: Triple-negative (TN) cancers (3.03%±0.56%) had significantly higher MTRasym values than luminal A (2.25%±1.00%) and luminal B (2.39%±0.81%) cancers (P=0.006, 0.012). HER2-enriched cancers (2.93%±0.71%) also had significantly higher MTRasym than luminal A cancers (P=0.039). MTRasym and ADC values were significantly higher in ER-negative (ER-) than they were in ER-positive (ER+) cancers (P<0.001, P=0.040), and MTRasym values were higher in PR-negative (PR-) and high-Ki-67 cancers (P<0.001, P=0.013). AUC values for MTRasym ranged from 0.699 to 0.799, depending on the subtype and biological marker comparison. MTRasym and ADC values showed a weak positive correlation with the Ki-67 index (r=0.37, P<0.001, and r=0.31, P=0.003). Conclusions: APTWI is more effective than DWI for differentiating BC subtypes and predicting biological markers, providing valuable insights for clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.